- Home
- JAZZ vs JXN Comparison
JAZZ vs JXN Comparison
Compare JAZZ & JXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- JXN
- Stock Information
- Founded
- JAZZ 2003
- JXN 1961
- Country
- JAZZ Ireland
- JXN United States
- Employees
- JAZZ N/A
- JXN N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- JXN Life Insurance
- Sector
- JAZZ Health Care
- JXN Finance
- Exchange
- JAZZ Nasdaq
- JXN Nasdaq
- Market Cap
- JAZZ 6.5B
- JXN 7.4B
- IPO Year
- JAZZ 2007
- JXN N/A
- Fundamental
- Price
- JAZZ $122.49
- JXN $90.36
- Analyst Decision
- JAZZ Buy
- JXN Hold
- Analyst Count
- JAZZ 14
- JXN 5
- Target Price
- JAZZ $173.93
- JXN $91.40
- AVG Volume (30 Days)
- JAZZ 539.6K
- JXN 654.1K
- Earning Date
- JAZZ 11-06-2024
- JXN 11-06-2024
- Dividend Yield
- JAZZ N/A
- JXN 3.08%
- EPS Growth
- JAZZ 458.10
- JXN N/A
- EPS
- JAZZ 7.04
- JXN N/A
- Revenue
- JAZZ $3,992,712,000.00
- JXN $4,063,000,000.00
- Revenue This Year
- JAZZ $7.51
- JXN N/A
- Revenue Next Year
- JAZZ $6.82
- JXN $4.08
- P/E Ratio
- JAZZ $17.38
- JXN N/A
- Revenue Growth
- JAZZ 5.23
- JXN 2072.73
- 52 Week Low
- JAZZ $99.06
- JXN $47.49
- 52 Week High
- JAZZ $134.17
- JXN $115.22
- Technical
- Relative Strength Index (RSI)
- JAZZ 53.16
- JXN 34.75
- Support Level
- JAZZ $121.22
- JXN $89.29
- Resistance Level
- JAZZ $126.23
- JXN $93.68
- Average True Range (ATR)
- JAZZ 2.83
- JXN 2.71
- MACD
- JAZZ -0.23
- JXN -0.90
- Stochastic Oscillator
- JAZZ 50.43
- JXN 7.57
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About JXN Jackson Financial Inc.
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail products offerings comprise annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. It manages the business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments.